| Chapter title |
Strategies for the Discovery and Development of New Antibiotics from Natural Products: Three Case Studies
|
|---|---|
| Chapter number | 498 |
| Book title |
How to Overcome the Antibiotic Crisis
|
| Published in |
Current topics in microbiology and immunology, January 2016
|
| DOI | 10.1007/82_2016_498 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-949282-7, 978-3-31-949284-1
|
| Authors |
Jennifer Herrmann, Tadeja Lukežič, Angela Kling, Sascha Baumann, Stephan Hüttel, Hrvoje Petković, Rolf Müller, Herrmann, Jennifer, Lukežič, Tadeja, Kling, Angela, Baumann, Sascha, Hüttel, Stephan, Petković, Hrvoje, Müller, Rolf |
| Abstract |
Natural products continue to be a predominant source for new anti-infective agents. Research at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and the Helmholtz Centre for Infection Research (HZI) is dedicated to the development of new lead structures against infectious diseases and, in particular, new antibiotics against hard-to-treat and multidrug-resistant bacterial pathogens. In this chapter, we introduce some of the concepts currently being employed in the field of antibiotic discovery. In particular, we will exemplarily illustrate three approaches: (1) Current sources for novel compounds are mainly soil-dwelling bacteria. In the course of our antimicrobial discovery program, a biodiverse collection of myxobacterial strains has been established and screened for antibiotic activities. Based on this effort, one successful example is presented in this chapter: Antibacterial cystobactamids were discovered and their molecular target, the DNA gyrase, was identified soon after the analysis of myxobacterial self-resistance making use of the information found in the respective biosynthesis gene cluster. (2) Besides our focus on novel natural products, we also apply strategies to further develop either neglected drugs or widely used antibiotics for which development of resistance in the clinical setting is an issue: Antimycobacterial griselimycins were first described in the 1960s but their development and use in tuberculosis therapy was not further pursued. We show how a griselimycin derivative with improved pharmacokinetic properties and enhanced potency against Mycobacterium tuberculosis revealed and validated a novel target for antibacterial therapy, the DNA sliding clamp. (3) In a third approach, biosynthetic engineering was used to modify and optimize natural products regarding their pharmaceutical properties and their production scale: The atypical tetracycline chelocardin is a natural product scaffold that was modified to yield a more potent derivative exhibiting activity against multidrug-resistant pathogens. This was achieved by genetic engineering of the producer strain and the resulting compound is now subject to further optimization by medicinal chemistry approaches. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Indonesia | 1 | 1% |
| Japan | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 64 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 15 | 22% |
| Researcher | 14 | 21% |
| Student > Ph. D. Student | 8 | 12% |
| Student > Master | 6 | 9% |
| Professor > Associate Professor | 4 | 6% |
| Other | 7 | 10% |
| Unknown | 13 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 15 | 22% |
| Chemistry | 10 | 15% |
| Agricultural and Biological Sciences | 8 | 12% |
| Immunology and Microbiology | 8 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 9% |
| Other | 7 | 10% |
| Unknown | 13 | 19% |